Press Releases Voyager Therapeutics, Inc.

Equities

VYGR

US92915B1061

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
8.45 ^USD	+0.24%		-0.35%	+0.12%

May. 16	Voyager Therapeutics, Inc Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer?s Disease	CI
May. 14	Wedbush Adjusts Voyager Therapeutics' PT to $8 From $10, Keeps Neutral Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease	May. 16	AQ
Voyager Therapeutics: Q1 Earnings Snapshot	May. 13	AQ
Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results	May. 13	AQ
Voyager Therapeutics Presents Data for Second-Generation, TRACER-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting	May. 09	AQ
Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting	May. 08	AQ
Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast	May. 06	AQ
Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting	Apr. 22	AQ
NORTHSTAR APPOINTS PETER PFREUNDSCHUH TO BOARD OF MANAGERS	Apr. 16	AQ
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment	Apr. 16	AQ
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	Mar. 27	AQ
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 26	AQ
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer	Mar. 13	AQ
Voyager Therapeutics: Q4 Earnings Snapshot	Feb. 28	AQ
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results	Feb. 28	AQ
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment	Feb. 27	AQ
Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment	Feb. 26	AQ
Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast	Feb. 21	AQ
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research	Feb. 20	AQ
Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference	Feb. 07	AQ
Voyager Therapeutics Announces Pricing of Public Offering	Jan. 04	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Voyager Therapeutics, Inc.

Equities

VYGR

US92915B1061

Press Releases

Filters